EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease

Jingfang Zhai, Canhua Hao, Xiaojing Wang, Yuexing Cao, Yinbo Pan, Min Zhou, Jie Sun, Chuanyou Li

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202300693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Jingfang Zhai und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Advanced Drug Delivery System, Key Lab for Rare & Uncommon Diseases of Shandong Province, Key Laboratory for Biotechnology…. Hauptthemen laut MEDLINE: Alzheimer Disease, Zebrafish, Cholinesterase Inhibitors, Drug Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: The Spring Sunshine Program is a project initiated by the Ministry of Education of China, Shandong Province Science and Technology Small and Medium Enterprises Innovation Ability Enhancement Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aβ 1−42 and acetylcholinesterase (AChE) are two key therapeutic targets for Alzheimer's disease (AD). The purpose of this study is to develop a dual‐target inhibitor that inhibits both of these targets by fusing the chemical structure of baicalein and donepezil. Among them, we modified the structure of baicalein to arylcoumarin, synthesized three kinds of structural compounds, and evaluated their biological activities. The results showed that compound 3b had the strongest inhibitory effect on AChE (IC 50 = 0.05 ± 0.02 µM), which was better than those of donepezil and baicalein. In addition, compound 3b has a strong ability to inhibit the aggregation of Aβ 1−42 and protect nerve cells, and it can also penetrate the blood–brain barrier well. Using a zebrafish behavioral analyzer test, it was found that compound 3b can alleviate the behavioral effects of AlCl 3 ‐induced zebrafish larval movement retardation, which has a certain guiding significance for simulating the movement disorders of AD patients. In summary, compound 3b is expected to become a multifunctional agent for treating and alleviating the symptoms of AD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseZebrafishCholinesterase InhibitorsDrug DesignAmyloid beta-PeptidesAcetylcholinesteraseAnimalsStructure-Activity RelationshipHumansPeptide FragmentsDonepezilBlood-Brain BarrierMolecular StructureFlavanonesDose-Response Relationship, DrugBehavior, Animal

Stichwörter der Autor:innen

AChEAlzheimer's diseaseAβ1−42dual‐target

Substanzen

Cholinesterase InhibitorsAmyloid beta-Peptidesamyloid beta-protein (1-42)AcetylcholinesterasePeptide FragmentsDonepezilFlavanones

Autor:innen und Institutionen

  • National Key Laboratory of Advanced Drug Delivery System, Key Lab for Rare & Uncommon Diseases of Shandong Province, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Scie…
  • Jinan Shangcheng Pharmatech. Co. Ltd., Jinan, China.
  • Jiangsu Second Chinese Medicine Hospital & The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Förderung

  • The Spring Sunshine Program is a project initiated by the Ministry of Education of China
  • Shandong Province Science and Technology Small and Medium Enterprises Innovation Ability Enhancement Project

Zitieren

APA

Zhai, J., Hao, C., Wang, X., Cao, Y., Pan, Y., Zhou, M., Sun, J., & Li, C. (2024). Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300693

Vancouver

Zhai J, Hao C, Wang X, Cao Y, Pan Y, Zhou M, et al. Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300693

BibTeX
@article{Zhai2024,
  author = {Zhai, Jingfang and Hao, Canhua and Wang, Xiaojing and Cao, Yuexing and Pan, Yinbo and Zhou, Min and Sun, Jie and Li, Chuanyou},
  title = {Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202300693}
}
Kostenlos starten →